Developer docs
API playgroundTry for free, no card

Search company profiles

Mytos

Full company profile

uuid00004fj

Namestring
Mytos
Legal namestring
Mytos
Websiteurl
mytos.bio
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Mytos is a UK-based biotechnology company that has developed iDEM™, an automated cell manufacturing platform designed to industrialize the production of regenerative medicines. The platform automates all unit operations in cell culture — coating, seeding, feeding, cell imaging, passaging, and harvesting — using the same 2D T-flash format as manual culture, which enables rapid protocol transfer without altering underlying biology. Mytos operates both a technology offering and a service offering: its automated CDMO (Contract Development and Manufacturing Organization) launched in October 2025 at CGT Catapult's 80,000 sqft Stevenage Manufacturing Innovation Centre, with stated capacity for up to 1,500 autologous doses or 25,000 allogeneic doses annually when clinical-ready in September 2026.

Mytos serves clinical-stage cell therapy developers across multiple therapeutic verticals — including Parkinson's, macular degeneration, hearing loss, bone regeneration, and heart failure — that face high manufacturing costs, operator-dependent batch failures, and difficulty scaling manual processes. Named partners include StemSight (ocular), Rinri Therapeutics (hearing loss), Novadip (bone regeneration), Aspen Neuroscience (Parkinson's), and Pluristyx (engineered iPSC lines). The company claims 10x labor reduction, 10x cleanroom footprint reduction, and up to 50% lower batch costs versus manual CDMOs, with no suite fees or device purchases required.

The business model combines CDMO services (managed services revenue per batch) with technology licensing potential, sold through B2B enterprise sales with dedicated product solutions and business development leadership. The CGT Catapult partnership provides embedded GMP and regulatory expertise. The company has raised over $24M cumulatively, including a $19M Series A in November 2023 led by Buckley Ventures, plus prior backing from Y Combinator, IQ Capital, Wing Venture Capital, Cur8 Capital, Pente Capital, and founders/executives of companies including Wayve, Dropbox, Segment, and Mercury.

Short descriptiontext

Mytos is a London-based biotechnology company that has developed iDEM™, an automated cell manufacturing platform, and operates an automated CDMO service for clinical-stage cell therapy developers producing regenerative medicines, reducing batch costs by up to 50% versus manual manufacturing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, automated CDMO services, regenerative medicine, iPSC bioprocessing, biotech manufacturing automation
Industry4 codes
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Special Industry Machinery (No Metalworking Machinery)3550
Product category
Cell Therapy Contract Manufacturing (CDMO)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1CDMO Services
TypeManaged Services
Description

Contract Development and Manufacturing Organization services for regenerative medicine companies. Customers pay for manufacturing services including Process & Analytical Development and Regulatory Support. Revenue generated through batch production fees with cost-efficient automated manufacturing.

globenewswire.com
2Technology Licensing
TypeLicensing Royalties
Description

iDEM platform made available to partners for automated cell manufacturing, enabling biotech companies to scale production of cell therapies from early clinical trials toward commercial-ready manufacturing.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Pricing details1 tier
1CDMO manufacturing services with 50% cost reduction vs manual alternatives
ModelUnit PricingBilling cadenceMulti-year contract
Notes

No suite fees, no device purchases required. Customer pays for manufacturing services. Claims significant cost savings through automation.

mytos.bio
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Mytos sells automated cell manufacturing services and licenses its proprietary iDEM™ automation platform to biotech and pharma companies developing regenerative cell therapies. Its core technology automates every unit operation in 2D T-flask cell culture — coating, seeding, feeding, imaging, passaging, and harvesting — within a closed system that delivers up to 10x reductions in labor and cleanroom footprint and ~50% lower batch costs than manual CDMOs. The company operates as an automated CDMO for stem-cell derived therapies (autologous and allogeneic, including iPSC-based products) and supports customers across process development, manufacturing, and regulatory activities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduces labour per batch by up to 10x compared to manual culture
+3 more records
Product overview1 text field

Mytos offers a unified platform combining its proprietary iDEM™ automation technology with integrated CDMO manufacturing services. The iDEM™ platform serves as the core technology that automates cell culture operations, while the Mytos CDMO service provides end-to-end manufacturing capabilities leveraging iDEM automation. The company also offers process and analytical development services along with regulatory support. Example applications include PSC expansion and cell banking, neural progenitor differentiation (for Parkinson's disease), cardiomyocyte differentiation (for heart failure), and RPE differentiation (for macular degeneration).

Product and service2 records
1iDEM™ (Intelligent Device for Automated Cell Manufacturing)
CategoryAutomated cell manufacturing platform
Description

Proprietary automated cell manufacturing platform that automates every unit operation in 2D T-flask cell culture — coating, seeding, feeding, cell imaging, passaging, and harvesting — within a closed system, enabling customers to port manual protocols to automation without altering biology and delivering up to 10x reductions in labor and cleanroom footprint.

2Mytos CDMO (Contract Development and Manufacturing Organization)
CategoryCell therapy contract manufacturing services
Description

Automated contract development and manufacturing service for regenerative cell therapies, covering process and analytical development, manufacturing, and regulatory support; delivers up to 50% lower batch costs than manual CDMOs with no suite fees or device purchases required.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-11
Description

Strategic collaboration to automate manufacturing of Pluristyx's clinical-grade iPSC cell lines for regenerative medicine. Mytos provides iDEM automation platform and CDMO infrastructure while Pluristyx contributes engineered iPSC platform including iACT immune-cloaking and FailSafe safety-switch technologies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-07
Description

Manufacturing partnership housing Mytos' first automated CDMO facility at CGT Catapult's 80,000 sqft Stevenage Manufacturing Innovation Centre. CGT Catapult provides GMP and regulatory expertise combined with Mytos' iDEM automation technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-03
Description

Strategic manufacturing collaboration to integrate Mytos' iDEM automated platform for ocular disease cell therapy applications. The partnership enables StemSight to scale production of cell therapies from early clinical trials toward commercial-ready manufacturing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-03
Description

Strategic manufacturing collaboration to integrate iDEM platform for hearing loss treatment (neuronal precursor cells). Enables Rinri to scale production using automated manufacturing without changing the biology of their existing process.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-03
Description

Strategic manufacturing collaboration to integrate iDEM platform for bone regeneration therapy. Enables Novadip to increase output of existing facilities without delaying scaling to build out new capacity.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-08
Description

Manufacturing collaboration where Aspen integrates Mytos' iDEM automated cell technology into its 22,000-square-foot facility for Parkinson's therapy. iDEM system enables Aspen to scale out for Phase 3 and ultimately commercialization, making more product at lower cost.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat6 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mytos

Cell Therapy Contract Manufacturing (CDMO)mytos.bio

Mytos is a London-based biotechnology company that has developed iDEM™, an automated cell manufacturing platform, and operates an automated CDMO service for clinical-stage cell therapy developers producing regenerative medicines, reducing batch costs by up to 50% versus manual manufacturing.

What Mytos does

Mytos is a UK-based biotechnology company that has developed iDEM™, an automated cell manufacturing platform designed to industrialize the production of regenerative medicines. The platform automates all unit operations in cell culture — coating, seeding, feeding, cell imaging, passaging, and harvesting — using the same 2D T-flash format as manual culture, which enables rapid protocol transfer without altering underlying biology. Mytos operates both a technology offering and a service offering: its automated CDMO (Contract Development and Manufacturing Organization) launched in October 2025 at CGT Catapult's 80,000 sqft Stevenage Manufacturing Innovation Centre, with stated capacity for up to 1,500 autologous doses or 25,000 allogeneic doses annually when clinical-ready in September 2026.

Mytos serves clinical-stage cell therapy developers across multiple therapeutic verticals — including Parkinson's, macular degeneration, hearing loss, bone regeneration, and heart failure — that face high manufacturing costs, operator-dependent batch failures, and difficulty scaling manual processes. Named partners include StemSight (ocular), Rinri Therapeutics (hearing loss), Novadip (bone regeneration), Aspen Neuroscience (Parkinson's), and Pluristyx (engineered iPSC lines). The company claims 10x labor reduction, 10x cleanroom footprint reduction, and up to 50% lower batch costs versus manual CDMOs, with no suite fees or device purchases required.

The business model combines CDMO services (managed services revenue per batch) with technology licensing potential, sold through B2B enterprise sales with dedicated product solutions and business development leadership. The CGT Catapult partnership provides embedded GMP and regulatory expertise. The company has raised over $24M cumulatively, including a $19M Series A in November 2023 led by Buckley Ventures, plus prior backing from Y Combinator, IQ Capital, Wing Venture Capital, Cur8 Capital, Pente Capital, and founders/executives of companies including Wayve, Dropbox, Segment, and Mercury.

Mytos firmographics

Firmographics
Name
Mytos
Legal name
Mytos
Website
https://mytos.bio
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Mytos is a London-based biotechnology company that has developed iDEM™, an automated cell manufacturing platform, and operates an automated CDMO service for clinical-stage cell therapy developers producing regenerative medicines, reducing batch costs by up to 50% versus manual manufacturing.
Ownership category
akta.pro rank

Mytos industry classification

Industry
Product category
Cell Therapy Contract Manufacturing (CDMO)
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Special Industry Machinery (No Metalworking Machinery) (3550)
akta.pro industry
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Cell therapy manufacturing
  • Automated CDMO services
  • Regenerative medicine
  • IPSC bioprocessing
  • Biotech manufacturing automation

Where Mytos is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Mytos business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. CDMO Services: Contract Development and Manufacturing Organization services for regenerative medicine companies. Customers pay for manufacturing services including Process & Analytical Development and Regulatory Support. Revenue generated through batch production fees with cost-efficient automated manufacturing.
  2. Technology Licensing: iDEM platform made available to partners for automated cell manufacturing, enabling biotech companies to scale production of cell therapies from early clinical trials toward commercial-ready manufacturing.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractCDMO manufacturing services with 50% cost reduction vs manual alternatives

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Mytos product offering

Product offering

Core offering

Mytos sells automated cell manufacturing services and licenses its proprietary iDEM™ automation platform to biotech and pharma companies developing regenerative cell therapies. Its core technology automates every unit operation in 2D T-flask cell culture — coating, seeding, feeding, imaging, passaging, and harvesting — within a closed system that delivers up to 10x reductions in labor and cleanroom footprint and ~50% lower batch costs than manual CDMOs. The company operates as an automated CDMO for stem-cell derived therapies (autologous and allogeneic, including iPSC-based products) and supports customers across process development, manufacturing, and regulatory activities.

Product overview

Mytos offers a unified platform combining its proprietary iDEM™ automation technology with integrated CDMO manufacturing services. The iDEM™ platform serves as the core technology that automates cell culture operations, while the Mytos CDMO service provides end-to-end manufacturing capabilities leveraging iDEM automation. The company also offers process and analytical development services along with regulatory support. Example applications include PSC expansion and cell banking, neural progenitor differentiation (for Parkinson's disease), cardiomyocyte differentiation (for heart failure), and RPE differentiation (for macular degeneration).

Differentiator

Problem solved

Functional benefit

Products and services

  • iDEM™ (Intelligent Device for Automated Cell Manufacturing) Proprietary automated cell manufacturing platform that automates every unit operation in 2D T-flask cell culture — coating, seeding, feeding, cell imaging, passaging, and harvesting — within a closed system, enabling customers to port manual protocols to automation without altering biology and delivering up to 10x reductions in labor and cleanroom footprint.
  • Mytos CDMO (Contract Development and Manufacturing Organization) Automated contract development and manufacturing service for regenerative cell therapies, covering process and analytical development, manufacturing, and regulatory support; delivers up to 50% lower batch costs than manual CDMOs with no suite fees or device purchases required.

Quantifiable outcome

  • Reduces labour per batch by up to 10x compared to manual culture
  • +3 more outcomes

Companies that use Mytos

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Mytos technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Mytos partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • PluristyxcoreStrategic or Co-development Partner · 11 December 2025Strategic collaboration to automate manufacturing of Pluristyx's clinical-grade iPSC cell lines for regenerative medicine. Mytos provides iDEM automation platform and CDMO infrastructure while Pluristyx contributes engineered iPSC platform including iACT immune-cloaking and FailSafe safety-switch technologies.
  • Cell and Gene Therapy Catapult (CGT Catapult)coreStrategic or Co-development Partner · 7 October 2025Manufacturing partnership housing Mytos' first automated CDMO facility at CGT Catapult's 80,000 sqft Stevenage Manufacturing Innovation Centre. CGT Catapult provides GMP and regulatory expertise combined with Mytos' iDEM automation technology.
  • StemSightcoreStrategic or Co-development Partner · 3 September 2025Strategic manufacturing collaboration to integrate Mytos' iDEM automated platform for ocular disease cell therapy applications. The partnership enables StemSight to scale production of cell therapies from early clinical trials toward commercial-ready manufacturing.
  • Rinri TherapeuticscoreStrategic or Co-development Partner · 3 September 2025Strategic manufacturing collaboration to integrate iDEM platform for hearing loss treatment (neuronal precursor cells). Enables Rinri to scale production using automated manufacturing without changing the biology of their existing process.
  • NovadipcoreStrategic or Co-development Partner · 3 September 2025Strategic manufacturing collaboration to integrate iDEM platform for bone regeneration therapy. Enables Novadip to increase output of existing facilities without delaying scaling to build out new capacity.
  • Aspen NeurosciencecoreStrategic or Co-development Partner · 8 January 2025Manufacturing collaboration where Aspen integrates Mytos' iDEM automated cell technology into its 22,000-square-foot facility for Parkinson's therapy. iDEM system enables Aspen to scale out for Phase 3 and ultimately commercialization, making more product at lower cost.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Mytos competitors and assessment

Company assessment

Market position

Competitive moat6 records

Key highlights7 records

Customer concentration

Mytos social profiles

Digital presence

Mytos financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mytos leadership team

Management profile

Number of profiles

Profiles10 records

Mytos funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mytos M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mytos

What does Mytos do?

Mytos sells automated cell manufacturing services and licenses its proprietary iDEM™ automation platform to biotech and pharma companies developing regenerative cell therapies. Its core technology automates every unit operation in 2D T-flask cell culture — coating, seeding, feeding, imaging, passaging, and harvesting — within a closed system that delivers up to 10x reductions in labor and cleanroom footprint and ~50% lower batch costs than manual CDMOs. The company operates as an automated CDMO for stem-cell derived therapies (autologous and allogeneic, including iPSC-based products) and supports customers across process development, manufacturing, and regulatory activities.

Is Mytos a public or private company?

Mytos is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mytos founded?

Mytos was founded in 2019. It employs 11 to 50 people.

Where is Mytos based?

Mytos is headquartered in London, United Kingdom, in the Europe region.

How does Mytos make money?

Two revenue lines are on record. CDMO Services are the primary driver. The others are technology Licensing.

Does Mytos have an API?

No public API is recorded for Mytos.

What industry is Mytos in?

Mytos's product category is Cell Therapy Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish). Its NAICS code is 3254 and its SIC code is 3550.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceMytos Launches Automated CDMO for Scalable, Low-Cost Manufacturing of Stem-Cell Derived TherapiesMytos, a London-based biotechnology company, has launched its automated contract development and manufacturing organization (CDMO) for scalable, low-cost manufacturing of stem-cell derived therapies, with its first facility housed at the Cell and Gene Therapy Catapult's Stevenage Manufacturing Innovation Centre in the UK. The facility, powered by Mytos' iDEM automation technology and targeting clinical readiness by September 2026, aims to deliver up to 1,500 autologous doses or 25,000 allogeneic doses annually. This launch represents the first of several planned global sites as Mytos seeks to build the manufacturing backbone needed to bring regenerative medicines to patients worldwide.Business Wire BlogMytos Launches Automated CDMO for Scalable, Low-Cost Manufacturing of Stem-Cell Derived TherapiesMytos launched its automated CDMO at CGT Catapult's Stevenage facility, targeting clinical readiness by September 2026. The site can deliver up to 1,500 autologous or 25,000 allogeneic doses annually, with additional cleanroom space available. This is the first of several planned global sites to scale regenerative medicine manufacturing.BioSpaceMytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy TrialsMytos, a London-based biotechnology company automating cell manufacturing, announced new manufacturing collaborations with StemSight, Rinri Therapeutics, and Novadip to integrate its iDEM automated platform across diverse therapeutic applications including ocular diseases, hearing loss, and bone regeneration. The partnerships represent a validation of Mytos' technology, enabling each biotech company to scale production of cell therapies from early clinical trials toward commercial-ready manufacturing. The collaborations reflect a broader industry shift toward automation in advanced cell therapies as the field matures toward patient-scale delivery.Business Wire BlogMytos Announces Manufacturing Collaboration with Aspen Neuroscience in Parkinson’s DiseaseMytos and Aspen Neuroscience announced a collaboration to automate manufacturing of autologous dopaminergic neuronal precursor cells for ANPD001, a Parkinson's disease cell therapy. Aspen will integrate Mytos' iDEM automated cell culture technology into its Torrey Pines facility, with potential substantial payments to Mytos. The partnership aims to scale production for growing patient demand.FinSMEsMytos Raises $19M in Series A FundingMytos, a London-based automated cell manufacturing company, raised $19M in Series A funding led by Buckley Ventures with participation from IQ Capital and Wing VC. The funds will accelerate manufacturing and distribution of its automated cell production system to more biotech and pharma companies. The platform automates cell manufacturing, including heart cells from stem cells.ForbesThis Startup Just Raised $19 Million To Bring An Industrial Revolution To BiologyMytos, a startup that automates cell culture growth, raised $19 million in a Series A led by Buckley Ventures. The company's fluidic system automates nutrient delivery and monitoring, enabling growth of over a dozen cell lines. The funding will accelerate development of new cell lines and potential automation of cell-based treatments.Business Wire BlogMytos Announces $19M Series A Funding to Automate Human Cell Manufacturing and Further Accelerate GrowthMytos closed $19M in Series A financing led by Buckley Ventures, with participation from IQ Capital and Wing VC. The funding will accelerate its automated cell production system to more biotech and pharma companies. The company plans to expand its sales and development team.PentecapitalMytos - An independent venture studioMytos has developed machines that automate the growth of human cells, enabling pharma and biotech companies to manipulate and monitor cell batches remotely via the cloud. The company is collaborating with major pharmaceutical firms, potentially transforming the traditional drug development process. Founded in 2018, Mytos aims to modernize the industry's methods of cell testing and cultivation.Medical BuyerMytos secures USD 19M to automate human cell manufacturingMytos has closed a $19 million Series A financing round led by Buckley Ventures to accelerate the manufacturing and distribution of its automated human cell production system. The funding will support the expansion of the company's sales and development teams to meet growing demand from biotech and pharmaceutical companies for automated cell culture solutions.MedicaldesigndevelopmentMytos Raises $19M to Automate Human Cell ManufacturingMytos has closed a $19 million Series A financing round led by Buckley Ventures, with participation from IQ Capital and Wing VC. The company intends to use the funds to accelerate the manufacturing and distribution of its automated human cell production system to biotech and pharma companies globally. This automation addresses critical bottlenecks in drug development by improving cell quality consistency and reducing manual labor.